RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Purpose: Previously, Kawasaki disease (KD) treatment with low-dose aspirin was administered for 6–8 weeks after the acute phase. However, inflammatory marker levels normalize before 6–8 weeks. In this study, we aimed to investigate the clinical outcome of short-term low-dose aspirin treatment based on inflammatory and thrombotic marker levels.
Methods: We performed a retrospective review of the medical records of patients with KD who were hospitalized at Chungnam National University Hospital between September 2012 and May 2014.
When fever subsided, low-dose aspirin treatment was started. Inflammatory (white blood cell count, erythrocyte sedimentation rate, and C-reactive protein) and thrombotic markers (D-dimer) were monitored at follow-ups conducted in 1- to 2-week intervals. The low-dose aspirin administration was terminated when both markers were normalized and no cardiovascular complications were observed.
Results: Eighty-four patients with KD (complete KD, n=49; incomplete KD, n=35) were enrolled. The inflammatory and thrombotic marker levels were normalized within 3–4 weeks on average. At the beginning the low-dose aspirin treatment, 9 patients had coronary artery lesions but 75 did not. When the low-dose aspirin administration was terminated at the time the inflammatory marker levels were normalized, no new CALs developed during the follow-up at 6–8 weeks.
Conclusion: Most of the inflammatory marker levels were normalized within 3–4 weeks after the acute phase of KD. New cardiovascular complications did not develop during the course of the short-term aspirin treatment based on the inflammatory marker levels, clinical findings, and echocardiography.

참고문헌 (Reference)

1 오일지, "가와사끼병에서 발병 6주째에 시행하는 추적검사의임상적 유용성에 관한 고찰" 대한소아과학회 49 (49): 672-676, 2006

2 Akagi T, "Salicylate treatment in Kawasaki disease: high dose or low dose?" 150 : 642-646, 1991

3 Mori M, "Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease" 137 : 177-180, 2000

4 Egami K, "Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease" 149 : 237-240, 2006

5 Sano T, "Prediction of non-responsiveness to standard high-dose gamma -globulin therapy in patients with acute Kawasaki disease before starting initial treatment" 166 : 131-137, 2007

6 Harada K, "Intravenous gamma-globulin treatment in Kawasaki disease" 33 : 805-810, 1991

7 Wallace CA, "Initial intravenous gammaglobulin treatment failure in Kawasaki disease" 105 : E78-, 2000

8 McMorrow Tuohy AM, "How many echocardiograms are necessary for follow-up evaluation of patients with Kawasaki disease?" 88 : 328-330, 2001

9 JCS Joint Working Group, "Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version" 78 : 2521-2562, 2014

10 Kobayashi T, "External validation of a scoring system to predict resistance to intravenous immunoglobulin" 150 : e37-, 2007